This afternoon we watched ResMed drop -3.6% to a price of $228.81 per share. The Large-Cap Medical Instruments & Supplies company is now trading -9.6% below its average target price of $253.11. Analysts have set target prices ranging from $190.0 to $283.0 per share for ResMed, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 5.9%, and a short ratio of 8.27. The company's insiders own 0.77% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 61.3% of ResMed's shares being owned by this investor type.
Institutions Invested in ResMed
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Vanguard Group Inc | 12% | 18,012,872 | $4,121,615,350 |
| 2024-09-30 | Blackrock Inc. | 8% | 11,914,690 | $2,726,259,821 |
| 2024-09-30 | State Street Corporation | 4% | 6,261,633 | $1,432,755,570 |
| 2024-09-30 | Bank Of New York Mellon Corporation | 4% | 5,708,454 | $1,306,179,915 |
| 2024-09-30 | Morgan Stanley | 3% | 4,476,564 | $1,024,305,002 |
| 2024-09-30 | Geode Capital Management, LLC | 3% | 3,858,814 | $882,954,534 |
| 2024-09-30 | Invesco Ltd. | 1% | 1,758,963 | $402,477,123 |
| 2024-09-30 | Northern Trust Corporation | 1% | 1,411,926 | $323,069,851 |
| 2024-09-30 | Legal & General Group PLC | 1% | 1,115,957 | $255,347,703 |
| 2024-09-30 | Charles Schwab Investment Management, Inc. | 1% | 924,047 | $211,435,816 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on ResMed.
